Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis.

Publication Year: 2023

DOI:
10.1186/s13098-023-01195-7

PMCID:
PMC10612199

PMID:
37891683

Journal Information

Full Title: Diabetol Metab Syndr

Abbreviation: Diabetol Metab Syndr

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology & Metabolism

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Competing interestsThe authors declare no competing interests. Ethics approval and consent to participateThis article does not contain any studies with human participants or animals performed by any of the authors. Consent for publicationNot applicable. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This work was supported by the Research Fund for Clinical Pharmacy of China International Medical Foundation (Z-2021-46-2101 Hu); National Natural Science Foundation of China (81973289 Fan)."

Evidence found in paper:

"This research was operated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [, ], which protocol was registered in PROSPERO (CRD42021264640)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025